Amarin Decision Could Spur Pressure Against FDA On Supplement Claim Policy
This article was originally published in The Tan Sheet
First Amendment advocate Jonathan Emord says the industry bows to FDA “intimidation” in not making truthful claims for their products. But the federal district court ruling for Amarin is the latest decision to strike against FDA’s policy on regulating supplement label claims, he says.
Register for our free email digests: